CN107898788A - A kind of hypoglycemic pharmaceutical composition and preparation method thereof - Google Patents
A kind of hypoglycemic pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN107898788A CN107898788A CN201711092627.4A CN201711092627A CN107898788A CN 107898788 A CN107898788 A CN 107898788A CN 201711092627 A CN201711092627 A CN 201711092627A CN 107898788 A CN107898788 A CN 107898788A
- Authority
- CN
- China
- Prior art keywords
- parts
- irp88
- stevioside
- ethanol
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 55
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims abstract description 46
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 25
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 25
- 239000011347 resin Substances 0.000 claims abstract description 25
- 229920005989 resin Polymers 0.000 claims abstract description 25
- 239000000741 silica gel Substances 0.000 claims abstract description 25
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 25
- 229940013618 stevioside Drugs 0.000 claims abstract description 25
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000019202 steviosides Nutrition 0.000 claims abstract description 25
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims abstract description 23
- 229960005095 pioglitazone Drugs 0.000 claims abstract description 23
- 229960002354 repaglinide Drugs 0.000 claims abstract description 23
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 20
- 229960004329 metformin hydrochloride Drugs 0.000 claims abstract description 18
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims abstract description 18
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960000540 polacrilin potassium Drugs 0.000 claims abstract description 17
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 238000005342 ion exchange Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims 4
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 10
- 239000008103 glucose Substances 0.000 abstract description 10
- 230000000295 complement effect Effects 0.000 abstract description 4
- 239000003472 antidiabetic agent Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to pharmaceutical technology field, specifically discloses a kind of hypoglycemic pharmaceutical composition and preparation method thereof, by weight fraction meter, is made of following raw material：5 10 parts of 5 10 parts of Repaglinide, 15 20 parts of Metformin hydrochloride, 5 10 parts of Pioglitazone, 10 15 parts of D-sorbite, 0.1 0.5 parts of superfine silica gel powder, 15 parts of polacrilin potassium resin (IRP88), 0.1 0.5 parts of stevioside and ethanol.The different hypoglycemic drug of several effects is combined by the present invention, has synergistic effect each other, has complementary advantages, improve curative effect, effectively control blood glucose, reduce complication, can also effectively lose weight while blood glucose is reduced, reduces blood fat etc..
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of hypoglycemic pharmaceutical composition and preparation method thereof.
Background technology
Diabetes (Diabetes Inellitus) are a kind of metabolic diseases of multi-pathogenesis, its main feature is that chronic hyperglycemia,
It is disorderly with sugar, fat and protein metabolism caused by insulin secretion and/or effect defect.Diabetes can betide any
Age, as the course of disease extends, the easily histopathology infringement such as concurrent whole body nerve, capilary and macroangiopathy, and can causing
Chronic, the progressive lesion of the histoorgans such as the heart, brain, kidney, nerve and eye, so that final occur blindness, lower limb gangrene, uremic
Disease, headstroke or myocardial infarction, or even threat to life.With the improvement of living standards, diabetes become a kind of common disease, its
Incidence is also increasing year by year.At present, the illness rate of developed country's diabetes is up to 5%-10%, the illness rate in China also oneself
Up to 3%.More than 90% is diabetes B in diabetic, and the ability that diabetes B produces insulin in patient body is not complete
Complete to lose, some patient's body insulin even produces excessively, but since the Insulin Resistance of body strengthens, and make pancreas islet
The action effect unobvious of element, therefore the insulin deficit of patient's body is a kind of opposite shortage.
At present, the treatment common medicine of diabetes has sulfonylureas, biguanides and alpha-glucosidase restrainer, independent medication
There are it is different degrees of the defects of, dosage is big, toxic side effect is obvious etc..Therefore, it is necessary to develop a kind of compound preparation, will act on
The different several drugs of mechanism combine, and have complementary advantages, and improve curative effect, effectively control blood glucose, reduce complication.
The content of the invention
To solve the above-mentioned problems, the present invention provides kind of hypoglycemic pharmaceutical composition and preparation method thereof, will act on machine
Manage different several drugs to combine, have complementary advantages, improve curative effect, effectively control blood glucose, reduce complication.
The present invention is only applicable in and simple diabetic, there is other diseases or hepatic and kidney function obstacle person disabling.
The technical solution that the present invention solves above-mentioned technical problem is as follows：A kind of hypoglycemic pharmaceutical composition, parts by weights
Number meter, is made of following raw material：5-10 parts of Repaglinide, 15-20 parts of Metformin hydrochloride, 5-10 parts of Pioglitazone, sorbose
10-15 parts of alcohol, 0.1-0.5 parts of superfine silica gel powder, 1-5 parts of polacrilin potassium resin (IRP88), 0.1-0.5 parts of stevioside and ethanol
5-10 parts.
Based on the above technical solutions, the present invention can also be improved as follows.
Preferably, a kind of hypoglycemic pharmaceutical composition, by weight fraction meter, are made of following raw material：Repaglinide 5
Part, 20 parts of Metformin hydrochloride, 5 parts of Pioglitazone, 15 parts of D-sorbite, 0.5 part of superfine silica gel powder, polacrilin potassium resin
(IRP88) 8 parts of 4 parts, 0.2 part of stevioside and ethanol.
Preferably, a kind of hypoglycemic pharmaceutical composition, by weight fraction meter, are made of following raw material：Repaglinide 10
Part, 15 parts of Metformin hydrochloride, 10 parts of Pioglitazone, 10 parts of D-sorbite, 0.3 part of superfine silica gel powder, polacrilin potassium resin
(IRP88) 10 parts of 5 parts, 0.1 part of stevioside and ethanol.
Preferably, a kind of hypoglycemic pharmaceutical composition, by weight fraction meter, are made of following raw material：Repaglinide 8
Part, 18 parts of Metformin hydrochloride, 8 parts of Pioglitazone, 12 parts of D-sorbite, 0.3 part of superfine silica gel powder, polacrilin potassium resin
(IRP88) 8 parts of 3 parts, 0.5 part of stevioside and ethanol.
Preferably, a kind of hypoglycemic pharmaceutical composition, by weight fraction meter, are made of following raw material：Repaglinide 5
Part, 15 parts of Metformin hydrochloride, 10 parts of Pioglitazone, 10 parts of D-sorbite, 0.3 part of superfine silica gel powder, polacrilin potassium resin
(IRP88) 5 parts of 5 parts, 0.1 part of stevioside and ethanol.
The present invention also provides a kind of preparation method of hypoglycemic pharmaceutical composition, concretely comprise the following steps：
Step 1：5-10 parts of Repaglinide, 15-20 parts of Metformin hydrochloride, Pioglitazone 5- are taken in pharmaceutical grade clean area
10 parts, 10-15 parts of D-sorbite, 0.1-0.5 parts of superfine silica gel powder, 1-5 parts of polacrilin potassium resin (IRP88), stevioside 0.1-
0.5 part and 5-10 parts of ethanol；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple
Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made,
It is spare to cross 80 mesh sieves；
Step 3：By drug containing toner and Repaglinide, Pioglitazone, D-sorbite, superfine silica gel powder, stevioside, ethanol
It is uniformly mixed, tabletting, tablet format 0.25g/ pieces.
Compared with prior art, the beneficial effects of the invention are as follows：
The different hypoglycemic drug of several effects is combined by the present invention, has synergistic effect each other, has complementary advantages,
Curative effect is improved, effectively controls blood glucose, complication is reduced, can also effectively lose weight while blood glucose is reduced, reduces blood fat
Deng.
Embodiment
The principles and features of the present invention are described below, and the given examples are served only to explain the present invention, is not intended to limit
Determine the scope of the present invention.
Embodiment 1
A kind of preparation of hypoglycemic pharmaceutical composition, concretely comprises the following steps：
Step 1：Repaglinide 5g, Metformin hydrochloride 20g, Pioglitazone 5g, sorbose are taken in pharmaceutical grade clean area
Alcohol 15g, superfine silica gel powder 0.5g, polacrilin potassium resin (IRP88) 4g, stevioside 0.2g and ethanol 8g；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple
Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made,
It is spare to cross 80 mesh sieves；
Step 3：By drug containing toner and Repaglinide, Pioglitazone, D-sorbite, superfine silica gel powder, stevioside, ethanol
It is uniformly mixed, tabletting, tablet format 0.25g/ pieces.
Embodiment 2
A kind of preparation of hypoglycemic pharmaceutical composition, concretely comprises the following steps：
Step 1：Repaglinide 5g, Metformin hydrochloride 20g, Pioglitazone 5g, sorbose are taken in pharmaceutical grade clean area
Alcohol 15g, superfine silica gel powder 0.5g, polacrilin potassium resin (IRP88) 4g, stevioside 0.2g and ethanol 8g；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple
Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made,
It is spare to cross 80 mesh sieves；
Step 3：By drug containing toner and Repaglinide, Pioglitazone, D-sorbite, superfine silica gel powder, stevioside, ethanol
It is uniformly mixed, tabletting, tablet format 0.25g/ pieces.
Embodiment 3
A kind of preparation of hypoglycemic pharmaceutical composition, concretely comprises the following steps：
Step 1：Repaglinide 8g, Metformin hydrochloride 18g, Pioglitazone 8g, sorbose are taken in pharmaceutical grade clean area
Alcohol 12g, superfine silica gel powder 0.3g, polacrilin potassium resin (IRP88) 3g, stevioside 0.5g and ethanol 8g；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple
Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made,
It is spare to cross 80 mesh sieves；
Step 3：By drug containing toner and Repaglinide, Pioglitazone, D-sorbite, superfine silica gel powder, stevioside, ethanol
It is uniformly mixed, tabletting, tablet format 0.25g/ pieces.
Embodiment 4：
A kind of preparation of hypoglycemic pharmaceutical composition, concretely comprises the following steps：
Step 1：Repaglinide 5g, Metformin hydrochloride 15g, Pioglitazone 10g, sorbose are taken in pharmaceutical grade clean area
Alcohol 10g, superfine silica gel powder 0.3g, polacrilin potassium resin (IRP88) 5g, stevioside 0.1g and ethanol 5g；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple
Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made,
It is spare to cross 80 mesh sieves；
Step 3：By drug containing toner and Repaglinide, Pioglitazone, D-sorbite, superfine silica gel powder, stevioside, ethanol
It is uniformly mixed, tabletting, tablet format 0.25g/ pieces.
Comparative example
A kind of preparation of hypoglycemic pharmaceutical composition, concretely comprises the following steps：
Step 1：Metformin hydrochloride 18g, D-sorbite 12g, superfine silica gel powder 0.3g, ripple is taken to draw in pharmaceutical grade clean area
Crin potassium resin (IRP88) 3g, stevioside 0.5g and ethanol 8g；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds ripple
Clarke woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made,
It is spare to cross 80 mesh sieves；
Step 3：Drug containing toner and D-sorbite, superfine silica gel powder, stevioside, ethanol are uniformly mixed, tabletting, tablet
Specification 0.25g/ pieces.
The test of pesticide effectiveness：
The hypoglycemic pharmaceutical composition of present invention implementation 1 is used for the clinical test of hyperglycemic patients, evaluates this implementation
The hypoglycemic effect of the hypoglycemic pharmaceutical composition of example 1.
1st, case selection：
100 diabetics, wherein male patient 58 are chosen, female patient 42, the oldest is 65 years old, minimum
For 38 years old, average age 48 years old, the course of disease -20 years 1 month, was randomly divided into experimental group and control group, every group of 50 people, patient is without it
Its disease or medical history, and hepatic and renal function is normal.
2nd, instructions of taking：
Experimental group takes pharmaceutical composition made from the embodiment of the present invention 1, three times per day, one at a time, takes before the meal, even
Continuous a week after taking.
Control group takes obtained pharmaceutical composition in comparative example of the present invention, three times per day, one at a time, takes before the meal,
Continuous a week after taking
3rd, curative effect judges：
It is effective：Patient blood glucose recovers to normal level；
Effectively, blood glucose level in patients has declined, but to drop to normal level；
Invalid, blood glucose level in patients is without any downward trend.
4th, test result：
The therapeutic effect contrast of hypoglycemic pharmaceutical composition in this implementation 1 hypoglycemic pharmaceutical composition and comparative example
It is shown in Table 1, total effective rate 92%, inefficiency 8%.Specific data are shown in Table 1.
1 test result contrast table of table
| It is effective | Effectively | It is invalid | Total effective rate | Inefficiency | |
| Experimental group | 24 | 22 | 4 | 92% | 8% |
| Control group | 18 | 20 | 12 | 76% | 24% |
In conclusion pharmaceutical composition hypoglycemic made from the embodiment of the present invention 1 can effectively control blood glucose, treatment effect
Fruit is more preferable.
Claims (6)
1. a kind of hypoglycemic pharmaceutical composition, it is characterised in that fraction meter by weight, is made of following raw material：Repaglinide
5-10 parts, 15-20 parts of Metformin hydrochloride, 5-10 parts of Pioglitazone, 10-15 parts of D-sorbite, 0.1-0.5 parts of superfine silica gel powder,
5-10 parts of 1-5 parts of polacrilin potassium resin (IRP88), 0.1-0.5 parts of stevioside and ethanol.
A kind of 2. hypoglycemic pharmaceutical composition according to claim 1, it is characterised in that fraction meter by weight, by with
Lower raw material composition：5 parts of Repaglinide, 20 parts of Metformin hydrochloride, 5 parts of Pioglitazone, 15 parts of D-sorbite, superfine silica gel powder 0.5
Part, 4 parts of polacrilin potassium resin (IRP88), 0.2 part of stevioside and 8 parts of ethanol.
A kind of 3. hypoglycemic pharmaceutical composition according to claim 1, it is characterised in that fraction meter by weight, by with
Lower raw material composition：10 parts of Repaglinide, 15 parts of Metformin hydrochloride, 10 parts of Pioglitazone, 10 parts of D-sorbite, superfine silica gel powder
10 parts of 0.3 part, 5 parts of polacrilin potassium resin (IRP88), 0.1 part of stevioside and ethanol.
A kind of 4. hypoglycemic pharmaceutical composition according to claim 1, it is characterised in that fraction meter by weight, by with
Lower raw material composition：8 parts of Repaglinide, 18 parts of Metformin hydrochloride, 8 parts of Pioglitazone, 12 parts of D-sorbite, superfine silica gel powder 0.3
Part, 3 parts of polacrilin potassium resin (IRP88), 0.5 part of stevioside and 8 parts of ethanol.
A kind of 5. hypoglycemic pharmaceutical composition according to claim 1, it is characterised in that fraction meter by weight, by with
Lower raw material composition：5 parts of Repaglinide, 15 parts of Metformin hydrochloride, 10 parts of Pioglitazone, 10 parts of D-sorbite, superfine silica gel powder 0.3
Part, 5 parts of polacrilin potassium resin (IRP88), 0.1 part of stevioside and 5 parts of ethanol.
6. a kind of preparation method of hypoglycemic pharmaceutical composition, it is characterised in that concretely comprise the following steps：
Step 1：5-10 parts of Repaglinide, 15-20 parts of Metformin hydrochloride, Pioglitazone 5-10 are taken in pharmaceutical grade clean area
Part, 10-15 parts of D-sorbite, 0.1-0.5 parts of superfine silica gel powder, 1-5 parts of polacrilin potassium resin (IRP88), stevioside 0.1-0.5
5-10 parts of part and ethanol；
Step 2：It is 1 in mass ratio that melbine, which is weighed, with water:30 ratio mixing, after being completely dissolved it, adds Andrea Pollack
Woods potassium (IRP88) resin carries out ion exchange, reacts 1h, filters washing, and in 60 DEG C of drying, drug containing toner is made, crosses 80
Mesh sieve is spare；
Step 3：Drug containing toner and Repaglinide, Pioglitazone, D-sorbite, superfine silica gel powder, stevioside, ethanol are mixed
Uniformly, tabletting, tablet format 0.25g/ pieces.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711092627.4A CN107898788A (en) | 2017-11-08 | 2017-11-08 | A kind of hypoglycemic pharmaceutical composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711092627.4A CN107898788A (en) | 2017-11-08 | 2017-11-08 | A kind of hypoglycemic pharmaceutical composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107898788A true CN107898788A (en) | 2018-04-13 |
Family
ID=61842819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711092627.4A Withdrawn CN107898788A (en) | 2017-11-08 | 2017-11-08 | A kind of hypoglycemic pharmaceutical composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107898788A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115154432A (en) * | 2022-07-22 | 2022-10-11 | 北京惠之衡生物科技有限公司 | Repaglinide tablet and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002758A (en) * | 1999-09-17 | 2007-07-25 | 诺瓦提斯公司 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
| CN101204394A (en) * | 2007-11-23 | 2008-06-25 | 杭州华东医药集团生物工程研究所有限公司 | Composite containing pioglitazone HCL and repaglinide |
| CN103251593A (en) * | 2013-06-04 | 2013-08-21 | 杭州朱养心药业有限公司 | Repaglinide/metformin composition |
| CN103432089A (en) * | 2013-09-02 | 2013-12-11 | 天津市聚星康华医药科技有限公司 | Metformin hydrochloride chewable tablet and preparation method thereof |
-
2017
- 2017-11-08 CN CN201711092627.4A patent/CN107898788A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002758A (en) * | 1999-09-17 | 2007-07-25 | 诺瓦提斯公司 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
| CN101204394A (en) * | 2007-11-23 | 2008-06-25 | 杭州华东医药集团生物工程研究所有限公司 | Composite containing pioglitazone HCL and repaglinide |
| CN103251593A (en) * | 2013-06-04 | 2013-08-21 | 杭州朱养心药业有限公司 | Repaglinide/metformin composition |
| CN103432089A (en) * | 2013-09-02 | 2013-12-11 | 天津市聚星康华医药科技有限公司 | Metformin hydrochloride chewable tablet and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115154432A (en) * | 2022-07-22 | 2022-10-11 | 北京惠之衡生物科技有限公司 | Repaglinide tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102551065B (en) | Blood sugar reducing food series | |
| CN107898788A (en) | A kind of hypoglycemic pharmaceutical composition and preparation method thereof | |
| CN102224924A (en) | Composition containing sea cucumber saponin and its application in food and medicine | |
| CN101829271B (en) | Traditional Chinese medicine compound with effect of treating diabetes and preparation method and application thereof | |
| CN107693555A (en) | A kind of medicine and purposes for treating diabetes | |
| CN102836349B (en) | Traditional Chinese medicine composition for treating diabetes and preparation method thereof | |
| CN107898795A (en) | A kind of hypoglycemic medicine and preparation method thereof | |
| CN107693526A (en) | A kind of hypoglycemic oral formulations and preparation method thereof | |
| CN101264203B (en) | Chinese and western medicine composition for treating diabetes | |
| CN104922445B (en) | A kind of Traditional Chinese medicine compound composition and the preparation method and application thereof with treatment heart failure effect | |
| CN102578451A (en) | Health-care food composite capable of decreasing blood sugar | |
| CN102715502B (en) | Preparation method of health food with function of anti-diabetes | |
| CN103285113B (en) | Pharmaceutical composition for preventing and/or treating diabetes mellitus | |
| CN113041300A (en) | Prescription for treating diabetes and its application | |
| CN106038668B (en) | A kind of medicine for controlling blood sugar concentration | |
| CN106466325B (en) | A kind of medicine, composition and preparation for preventing or treating diabetes | |
| CN105250339A (en) | Composition capable of decreasing blood sugar and preparation method thereof | |
| CN107714761A (en) | A kind of hypoglycemic medicine and purposes | |
| CN108159233A (en) | A kind of Chinese medicine composition for treating diabetes and preparation method thereof | |
| CN108079000A (en) | A kind of pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN104107323B (en) | A kind of traditional Chinese medicinal composition with effect of reducing blood sugar and preparation method thereof | |
| CN107648288A (en) | A kind of hypoglycemic medicine composition and purposes | |
| CN108245625A (en) | A kind of hypoglycemic composition and preparation method thereof and purposes | |
| CN1327879C (en) | Medicine for treating diabetes and its preparing method | |
| CN1172702C (en) | Sugar-free erigeron breviscapus granule and its prepn and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180413 |